Literature DB >> 3259443

Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

A G Leary1, K Ikebuchi, Y Hirai, G G Wong, Y C Yang, S C Clark, M Ogawa.   

Abstract

Currently available evidence suggests that in the steady state, the majority of hematopoietic stem cells are dormant in cell cycle and reside in the so-called G0 period. Studies in our laboratory indicated that once a stem cell leaves G0, its subsequent proliferation requires the presence of interleukin-3 (IL-3). Recently it was reported that interleukin-1 (IL-1) may stimulate stem cells to become sensitive to IL-3. In a separate study, we observed that interleukin-6 (IL-6, also known as B cell stimulatory factor-2/interferon beta 2) possesses synergism with IL-3, shortening the G0 period of murine hematopoietic stem cells. We report here that human IL-6 and IL-3 act synergistically in support of the proliferation of progenitors for human blast cell colonies and that IL-1 alpha reveals no synergism with IL-3 when tested against purified human marrow progenitors. Panned My-10+ human marrow cells were plated in culture and on day 14 of incubation, either IL-3, IL-6, IL-1 alpha or a combination of these factors was added to the cultures. Blast cell colony formation was analyzed daily between days 18 and 32 of culture. IL-6 or IL-1 alpha alone failed to support blast cell colony formation. In the presence of IL-3 alone, blast cell colonies continued to emerge between days 21 and 27. When a combination of IL-3 and IL-6 was added, blast cell colonies developed earlier than in cultures with IL-3 alone and twice as many blast cell colonies were identified. IL-1 alpha failed to augment IL-3-dependent blast cell colony formation. Replating studies of the individual blast cell colonies revealed various types of single as well as multilineage colonies. These observations suggest that IL-6 shortens the G0 period of human hematopoietic stem cells and that the reported synergistic activities of IL-1 on primitive hematopoietic cells may be indirect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259443

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

Review 1.  Regulation of hemopoietic cell development by interleukins 4, 5 and 6.

Authors:  D Rennick; S Hudak; G Yang; J Jackson
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

3.  Interleukin-6 and renal cell cancer: production, regulation, and growth effects.

Authors:  A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.

Authors:  K Yoshizaki; N Nishimoto; M Mihara; T Kishimoto
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Comparative analysis of the influences of IL-1, IL-3 and GM-CSF on the commitment of granulocyte-macrophage progenitors in vitro.

Authors:  J Maciejewski; H Weber; K Neuhaus; M Wächter; E Elstner; F R Seiler; H D Volk
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

6.  Stimulation of thrombopoiesis in mice by human recombinant interleukin 6.

Authors:  R J Hill; M K Warren; J Levin
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

7.  An assessment of myeloid colony-forming-cell generation in liquid human bone marrow cultures: influence of accessory cells and cytokines IL-1 alpha, beta and IL-6.

Authors:  R P Gooding; P G Riches; M Y Gordon
Journal:  Int J Exp Pathol       Date:  1993-04       Impact factor: 1.925

Review 8.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15

9.  Ferroportin and erythroid cells: an update.

Authors:  Luciano Cianetti; Marco Gabbianelli; Nadia Maria Sposi
Journal:  Adv Hematol       Date:  2010-08-11

Review 10.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.